Healthcare (Basel)
September 12, 2025
Anna Schuldt, Ian C. Clark, Yasmin Schmid et al.
1 citation
Background: Evidence is growing that psychedelic substances have positive effects in the setting of Palliative Care (PC), focusing on special needs in this patient population. After a scoping review of the literature, no published expert recommendations guiding best practice for psychedelic-assisted therapy (PAT) towards the end of life were identified. Objective: To draw conclusions from...
Cochrane Database of Systematic Reviews
September 11, 2024
Sivan Schipper, Kabir Nigam, Yasmin Schmid et al.
34 citations
Implications for practice Psychedelic-assisted therapy with classical psychedelics (psilocybin, LSD) may be effective for treating anxiety, depression, and possibly existential distress, in people facing a life-threatening disease. Psychedelic-assisted therapy seemed to be well tolerated, with no treatment-emergent serious adverse events reported in the studies included in this review. However,...
Cochrane Database of Systematic Reviews
November 21, 2022
Sivan Schipper, Kabir Nigam, Vanessa Piechotta et al.
4 citations
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the benefits and harms of psychedelic/entactogen‐assisted therapy compared to placebo or active comparators (e.g. antidepressants) for treatment of anxiety, depression, and existential distress in adult palliative care.
Psychiatric Annals
September 1, 2022
Michael Ljuslin, Kabir Nigam, Roxanne Sholevar et al.
4 citations
In addition to physical symptoms and treatment burden, people affected by serious illness experience psychological, social, and spiritual distress. Medical professionals who care for them, including psychiatrists and other mental health clinicians, attend to these multiple dimensions of suffering with the hope and promise of improving patients' quality of life. Yet anxiety, depression,...